Siemens Energy AG will sell its 32% stake in Spanish wind turbine towers maker Windar Renovables to British investment firm Bridgepoint Group.
Windar Renovables is a joint venture between Siemens Energy and the Spanish industrial group Daniel Alonso.
Bridgepoint is about to buy the entire stake of Siemens Energy and a portion of Daniel Alonso’s 68% shareholding.
Siemens Energy’s CEO Christian Bruch had earlier announced that the company intends to divest “peripheral” assets.
Windar Renovables, which has 1,500 employees worldwide, specializes in the manufacturing of towers for wind turbines and offshore foundations.
Windar Renovables was recently selected to produce transition pieces for the 1,400-MW East Anglia Three offshore wind project in UK waters.


China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



